ClinicalTrials.gg
CompletedNCT03768089Updated Jul 14, 2022Results posted

Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis

A Phase 1/2 interventional study of Placebo (matched to VX-121 suspension) and VX-121 (Suspension) in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 7 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-14.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Mar 2018, registered Dec 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.

Enrollment
21st of 43
115 · median 100
Started
2018
with 4 others
Phase 1/2
2 of 43
none open now
Registered
22nd of 43
by date
Lead sponsor
39 of 43
Vertex Pharmaceuticals Incorporated

Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 21st largest by enrollment, is one of 5 that started in 2018, is one of 2 in phase 1/2, and was the 22nd registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tezacaftor

tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tezacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate safety and tolerability of VX-121 in healthy subjects and in subjects with cystic fibrosis (CF).

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Part A, B, and C: Healthy Volunteers

    • Female subjects must be of non-
    • Between the ages of 18 and 55 years, inclusive
    • (BMI) of 18.0 to 32.0 kg/m2, inclusive, and a total body weight >50 kg
  • Part D: Subjects with CF

    • Heterozygous for F508del and an MF mutation (F/MF)
    • value ≥40% and ≤90% of predicted mean for age, sex, and height
    • Body weight ≥35 kg

Key Exclusion Criteria:

  • Part A, B and C: Healthy Volunteers

    • Any condition possibly affecting drug absorption
    • History of febrile illness or other acute illness within 5 days before the first study drug dose
  • Part D: Subjects with CF

    • History of cirrhosis with or without portal hypertension
    • History of solid organ or hematological transplantation
    • Lung infection with organisms associated with a more rapid decline in pulmonary status

Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
115 participants (actual)

Study arms

  • Placebo comparator
    Part A: Pooled Placebo (Cohorts A1-5; Except A3)

    Participants received single dose of placebo matched to VX-121.

    Drug: Placebo (matched to VX-121 suspension)

  • Experimental
    Part A: VX-121 (Cohort A1)

    Participants received single dose of VX-121 10 milligrams (mg).

    Drug: VX-121 (Suspension)

  • Experimental
    Part A: VX-121 (Cohort A2)

    Participants received single dose of VX-121 20 mg.

    Drug: VX-121 (Suspension)

  • Experimental
    Part A: VX-121 (Cohort A3)

    Participants received single dose of VX-121 5 mg or matched placebo without milk, followed by open label VX-121 5 mg with milk.

    Drug: Placebo (matched to VX-121 suspension) · Drug: VX-121 (Suspension)

  • Experimental
    Part A: VX-121 (Cohort A4)

    Participants received single dose of VX-121 40 mg.

    Drug: VX-121 (Suspension)

  • Experimental
    Part A: VX-121 (Cohort A5)

    Participants received single dose of VX-121 60 mg.

    Drug: VX-121 (Suspension)

  • Experimental
    Part A: VX-121 (Cohort A9)

    Participants received single dose of VX-121 10 mg suspension on Day 1, VX-121 10 mg tablet on Day 9, followed by VX-121 10 mg tablet with milk on Day 17.

    Drug: VX-121 (Suspension) · Drug: VX-121 (Tablet)

  • Placebo comparator
    Part B: Pooled Placebo (Cohorts B1-4)

    Participants received placebo matched to VX-121 for 10 days.

    Drug: Placebo (matched to VX-121 suspension)

  • Experimental
    Part B: VX-121 (Cohort B1)

    Participants received VX-121 10 mg once daily (qd) for 10 days.

    Drug: VX-121 (Suspension)

  • Experimental
    Part B: VX-121 (Cohort B2)

    Participants received VX-121 20 mg qd for 10 days.

    Drug: VX-121 (Suspension)

  • Experimental
    Part B: VX-121 (Cohort B3)

    Participants received VX-121 40 mg qd for 10 days.

    Drug: VX-121 (Suspension)

  • Experimental
    Part B: VX-121 (Cohort B4)

    Participants received VX-121 60 mg qd for 10 days.

    Drug: VX-121 (Suspension)

  • Placebo comparator
    Part C: Pooled Placebo (Cohorts C1-3)

    Participants received placebo matched to VX-121/TEZ/IVA for 14 days.

    Drug: Placebo (matched to VX-121 suspension) · Drug: Placebo (matched to TEZ/IVA) · Drug: Placebo (matched to IVA)

  • Experimental
    Part C: VX-121 (Cohort C1)

    Participants received VX-121 10 mg qd/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) for 14 days.

    Drug: VX-121 (Suspension) · Drug: TEZ/IVA · Drug: IVA

  • Experimental
    Part C: VX-121 (Cohort C2)

    Participants received VX-121 20 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 14 days.

    Drug: VX-121 (Suspension) · Drug: TEZ/IVA · Drug: IVA

  • Experimental
    Part C: VX-121 (Cohort C3)

    Participants received VX-121 5 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 14 days.

    Drug: VX-121 (Suspension) · Drug: TEZ/IVA · Drug: IVA

  • Placebo comparator
    Part D: Placebo

    Participants received placebo matched to VX-121/TEZ/IVA for 4 weeks.

    Drug: Placebo (matched to TEZ/IVA) · Drug: Placebo (matched to IVA) · Drug: Placebo (matched to VX-121 tablet)

  • Experimental
    Part D: VX-121/TEZ/IVA

    Participants received VX-121 5 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks.

    Drug: TEZ/IVA · Drug: IVA · Drug: VX-121 (Tablet)

Interventions

  • DrugPlacebo (matched to VX-121 suspension)

    Placebo matched to VX-121 suspension for oral administration.

  • Suspension for oral administration.

  • DrugTEZ/IVA

    Drug pages: Tezacaftor · Ivacaftor

    Fixed-dose combination tablet for oral administration.

    Also known as: VX-661/VX-770, tezacaftor/ivacaftor

  • DrugIVA

    Tablet for oral administration.

    Also known as: VX-770, ivacaftor

  • DrugPlacebo (matched to TEZ/IVA)

    Placebo matched to TEZ/IVA for oral administration.

  • DrugPlacebo (matched to IVA)

    Placebo matched to IVA for oral administration.

  • Tablet for oral administration.

  • DrugPlacebo (matched to VX-121 tablet)

    Placebo matched to VX-121 tablet for oral administration.

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 Through Safety Follow-up (up to Day 15 for Part A [except Cohorts A3 and A9], up to Day 26 for Cohort A3, up to Day 34 for Cohort A9, up to Day 20 for Part B, up to Day 24 for Part C and up to Week 9 for Part D)

Secondary outcomes

  1. Part A: Maximum Observed Concentration (Cmax) of VX-121

    Time frame: Cohorts A1-5 (Except A3): Pre-dose up to 240 hours post-dose; Cohorts A3 and A9: Pre-dose up to 168 hours post-dose

  2. Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC[0-last]) of VX-121

    Time frame: Cohorts A1-5 (Except A3): Pre-dose up to 240 hours post-dose; Cohorts A3 and A9: Pre-dose up to 168 hours post-dose

  3. Part B: Maximum Observed Concentration (Cmax) of VX-121

    Time frame: Day 1, Day 5, and Day 10

  4. Part B: Area Under the Concentration Versus Time Curve During the Dosing Interval (AUCtau) of VX-121

    Time frame: Day 1, Day 5, and Day 10

  5. Part B: Observed Pre-dose Plasma Concentration (Ctrough) of VX-121

    Time frame: Pre-dose at Day 5 and Day 10

  6. Part C: Maximum Observed Concentration (Cmax) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and, IVA and Its Metabolites (M1-IVA and M6-IVA)

    Time frame: Day 1, Day 7, and Day 14

  7. Part C: Area Under the Concentration Versus Time Curve During a Dosing Interval (AUCtau) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and IVA and Its Metabolites (M1-IVA and M6-IVA)

    Time frame: Day 1, Day 7, and Day 14

  8. Part C: Pre-dose Plasma Concentration (Ctrough) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and IVA and Its Metabolites (M1-IVA and M6-IVA)

    Time frame: Pre-dose at Day 7 and Day 14

  9. Part D: Maximum Observed Concentration (Cmax) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and IVA and Its Metabolites (M1-IVA and M6-IVA)

    Time frame: Day 1 and Day 15

  10. Part D: Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC[0-last]) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and IVA and Its Metabolites (M1-IVA and M6-IVA)

    Time frame: Day 1 and Day 15

  11. Part D: Pre-dose Plasma Concentration (Ctrough) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and IVA and Its Metabolites (M1-IVA and M6-IVA)

    Time frame: Pre-dose at Day 8, Day 15, and Day 29

  12. Part D: Absolute Change in Sweat Chloride (SwCl) Concentrations

    Sweat samples were collected using an approved collection device.

    Time frame: From Baseline Through Day 29

  13. Part D: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: From Baseline Through Day 29

07

Results

Posted Jul 14, 2022

Participant flow

A total of 115 unique participants enrolled in this study.

Part A
Participant flow — Part A
MilestonePart A: Pooled Placebo (Cohorts A1-5; Except A3)Part A: VX-121 (Cohort A1)Part A: VX-121 (Cohort A2)Part A: VX-121 (Cohort A3)Part A: VX-121 (Cohort A4)Part A: VX-121 (Cohort A5)Part A: VX-121 (Cohort A9)Part B: Pooled Placebo (Cohorts B1-4)Part B: VX-121 (Cohort B1)Part B: VX-121 (Cohort B2)Part B: VX-121 (Cohort B3)Part B: VX-121 (Cohort B4)Part C: Pooled Placebo (Cohorts C1-3)Part C: VX-121 (Cohort C1)Part C: VX-121 (Cohort C2)Part C: VX-121 (Cohort C3)Part D: PlaceboPart D: VX-121/TEZ/IVA
Started856666800000000000
Safety set856666800000000000
Completed856656800000000000
Not completed000010000000000000
Withdrew: Lost to follow-up000010000000000000
Part B
Participant flow — Part B
MilestonePart A: Pooled Placebo (Cohorts A1-5; Except A3)Part A: VX-121 (Cohort A1)Part A: VX-121 (Cohort A2)Part A: VX-121 (Cohort A3)Part A: VX-121 (Cohort A4)Part A: VX-121 (Cohort A5)Part A: VX-121 (Cohort A9)Part B: Pooled Placebo (Cohorts B1-4)Part B: VX-121 (Cohort B1)Part B: VX-121 (Cohort B2)Part B: VX-121 (Cohort B3)Part B: VX-121 (Cohort B4)Part C: Pooled Placebo (Cohorts C1-3)Part C: VX-121 (Cohort C1)Part C: VX-121 (Cohort C2)Part C: VX-121 (Cohort C3)Part D: PlaceboPart D: VX-121/TEZ/IVA
Started000000096666000000
Safety set000000096666000000
Completed000000096666000000
Not completed000000000000000000
Part C
Participant flow — Part C
MilestonePart A: Pooled Placebo (Cohorts A1-5; Except A3)Part A: VX-121 (Cohort A1)Part A: VX-121 (Cohort A2)Part A: VX-121 (Cohort A3)Part A: VX-121 (Cohort A4)Part A: VX-121 (Cohort A5)Part A: VX-121 (Cohort A9)Part B: Pooled Placebo (Cohorts B1-4)Part B: VX-121 (Cohort B1)Part B: VX-121 (Cohort B2)Part B: VX-121 (Cohort B3)Part B: VX-121 (Cohort B4)Part C: Pooled Placebo (Cohorts C1-3)Part C: VX-121 (Cohort C1)Part C: VX-121 (Cohort C2)Part C: VX-121 (Cohort C3)Part D: PlaceboPart D: VX-121/TEZ/IVA
Started000000000000668600
Safety set000000000000667600
Completed000000000000667600
Not completed000000000000001000
Withdrew: Randomized, never dosed000000000000001000
Part D
Participant flow — Part D
MilestonePart A: Pooled Placebo (Cohorts A1-5; Except A3)Part A: VX-121 (Cohort A1)Part A: VX-121 (Cohort A2)Part A: VX-121 (Cohort A3)Part A: VX-121 (Cohort A4)Part A: VX-121 (Cohort A5)Part A: VX-121 (Cohort A9)Part B: Pooled Placebo (Cohorts B1-4)Part B: VX-121 (Cohort B1)Part B: VX-121 (Cohort B2)Part B: VX-121 (Cohort B3)Part B: VX-121 (Cohort B4)Part C: Pooled Placebo (Cohorts C1-3)Part C: VX-121 (Cohort C1)Part C: VX-121 (Cohort C2)Part C: VX-121 (Cohort C3)Part D: PlaceboPart D: VX-121/TEZ/IVA
Started000000000000000039
Safety set000000000000000039
Completed000000000000000039
Not completed000000000000000000

Outcome measures

PrimarySafety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
From Day 1 Through Safety Follow-up (up to Day 15 for Part A [except Cohorts A3 and A9], up to Day 26 for Cohort A3, up to Day 34 for Cohort A9, up to Day 20 for Part B, up to Day 24 for Part C and up to Week 9 for Part D)
Reported as:
Number · participants
Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
participantsPart A: Pooled Placebo (Cohorts A1-5; Except A3)Part A: VX-121 (Cohort A1)Part A: VX-121 (Cohort A2)Part A: VX-121 (Cohort A3)Part A: VX-121 (Cohort A4)Part A: VX-121 (Cohort A5)Part A: VX-121 (Cohort A9)Part B: Pooled Placebo (Cohorts B1-4)Part B: VX-121 (Cohort B1)Part B: VX-121 (Cohort B2)Part B: VX-121 (Cohort B3)Part B: VX-121 (Cohort B4)Part C: Pooled Placebo (Cohorts C1-3)Part C: VX-121 (Cohort C1)Part C: VX-121 (Cohort C2)Part C: VX-121 (Cohort C3)Part D: PlaceboPart D: VX-121/TEZ/IVA
Participants With TEAEs142412773545436327
Participants With SAEs000000000000000010
SecondaryPart A: Maximum Observed Concentration (Cmax) of VX-121
Time frame:
Cohorts A1-5 (Except A3): Pre-dose up to 240 hours post-dose; Cohorts A3 and A9: Pre-dose up to 168 hours post-dose
Reported as:
Mean · microgram per milliliter (mcg/mL)
Part A: Maximum Observed Concentration (Cmax) of VX-121
microgram per milliliter (mcg/mL)Part A: VX-121 (Cohort A1)Part A: VX-121 (Cohort A2)Part A: VX-121 (Cohort A3: Without Milk)Part A: VX-121 (Cohort A3: With Milk)Part A: VX-121 (Cohort A4)Part A: VX-121 (Cohort A5)Part A: VX-121 (Cohort A9: Suspension)Part A: VX-121 (Cohort A9: Tablet Without Milk)Part A: VX-121 (Cohort A9: Tablet With Milk)
Part A: Maximum Observed Concentration (Cmax) of VX-1210.134 ± 0.02950.247 ± 0.05150.0705 ± 0.01520.061 ± 0.01430.893 ± 0.2161.04 ± 0.2630.181 ± 0.04580.178 ± 0.04470.156 ± 0.0352
SecondaryPart A: Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC[0-last]) of VX-121
Time frame:
Cohorts A1-5 (Except A3): Pre-dose up to 240 hours post-dose; Cohorts A3 and A9: Pre-dose up to 168 hours post-dose
Reported as:
Mean · microgram*hour per milliliter (mcg*h/mL)
Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC[0-last]) of VX-121
microgram*hour per milliliter (mcg*h/mL)Part A: VX-121 (Cohort A1)Part A: VX-121 (Cohort A2)Part A: VX-121 (Cohort A3: Without Milk)Part A: VX-121 (Cohort A3: With Milk)Part A: VX-121 (Cohort A4)Part A: VX-121 (Cohort A5)Part A: VX-121 (Cohort A9: Suspension)Part A: VX-121 (Cohort A9: Tablet Without Milk)Part A: VX-121 (Cohort A9: Tablet With Milk)
Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC[0-last]) of VX-1217.72 ± 1.9320.7 ± 7.036.32 ± 2.545.36 ± 2.0972.2 ± 28.966.6 ± 9.1815.7 ± 3.8814.6 ± 3.8513.1 ± 2.56
SecondaryPart B: Maximum Observed Concentration (Cmax) of VX-121
Time frame:
Day 1, Day 5, and Day 10
Reported as:
Mean · mcg/mL
Part B: Maximum Observed Concentration (Cmax) of VX-121
mcg/mLPart B: VX-121 (Cohort B1)Part B: VX-121 (Cohort B2)Part B: VX-121 (Cohort B3)Part B: VX-121 (Cohort B4)
Day 10.153 ± 0.02600.418 ± 0.06670.803 ± 0.05291.43 ± 0.217
Day 50.497 ± 0.08891.41 ± 0.3162.67 ± 0.5644.36 ± 0.789
Day 100.574 ± 0.1221.94 ± 0.4103.07 ± 0.6675.07 ± 0.803
SecondaryPart B: Area Under the Concentration Versus Time Curve During the Dosing Interval (AUCtau) of VX-121
Time frame:
Day 1, Day 5, and Day 10
Reported as:
Mean · mcg*h/mL
Part B: Area Under the Concentration Versus Time Curve During the Dosing Interval (AUCtau) of VX-121
mcg*h/mLPart B: VX-121 (Cohort B1)Part B: VX-121 (Cohort B2)Part B: VX-121 (Cohort B3)Part B: VX-121 (Cohort B4)
Day 12.62 ± 0.4357.11 ± 1.2714.4 ± 1.0827.5 ± 4.30
Day 510.3 ± 1.8430.1 ± 6.7653.8 ± 10.786.6 ± 16.6
Day 1011.5 ± 2.5238.2 ± 9.2658.7 ± 12.697.5 ± 17.2
SecondaryPart B: Observed Pre-dose Plasma Concentration (Ctrough) of VX-121
Time frame:
Pre-dose at Day 5 and Day 10
Reported as:
Mean · mcg/mL
Part B: Observed Pre-dose Plasma Concentration (Ctrough) of VX-121
mcg/mLPart B: VX-121 (Cohort B1)Part B: VX-121 (Cohort B2)Part B: VX-121 (Cohort B3)Part B: VX-121 (Cohort B4)
Day 50.391 ± 0.06941.16 ± 0.2662.07 ± 0.5372.94 ± 0.759
Day 100.484 ± 0.1091.64 ± 0.4142.40 ± 0.6373.81 ± 0.792
SecondaryPart C: Maximum Observed Concentration (Cmax) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and, IVA and Its Metabolites (M1-IVA and M6-IVA)
Time frame:
Day 1, Day 7, and Day 14
Reported as:
Mean · mcg/mL
Part C: Maximum Observed Concentration (Cmax) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and, IVA and Its Metabolites (M1-IVA and M6-IVA)
mcg/mLPart C: VX-121 (Cohort C1)Part C: VX-121 (Cohort C2)Part C: VX-121 (Cohort C3)
VX-121: Day 10.212 ± 0.05010.408 ± 0.1220.0728 ± 0.0102
VX-121: Day 71.18 ± 0.7351.77 ± 0.4160.364 ± 0.122
VX-121: Day 141.39 ± 0.6512.14 ± 0.4760.385 ± 0.108
TEZ: Day 15.97 ± 1.336.75 ± 0.9365.11 ± 1.35
TEZ: Day 79.48 ± 3.098.72 ± 0.5617.50 ± 1.24
TEZ: Day 149.49 ± 3.769.08 ± 0.5477.27 ± 1.40
M1-TEZ: Day 11.09 ± 0.3271.24 ± 0.3991.12 ± 0.259
M1-TEZ: Day 75.07 ± 1.106.48 ± 1.485.20 ± 0.606
M1-TEZ: Day 146.44 ± 1.368.12 ± 1.416.70 ± 1.19
M2-TEZ: Day 10.521 ± 0.1910.622 ± 0.3900.662 ± 0.320
M2-TEZ: Day 74.79 ± 2.036.16 ± 2.175.56 ± 3.67
M2-TEZ: Day 146.45 ± 2.888.78 ± 3.549.07 ± 6.13
IVA: Day 11.02 ± 0.1581.00 ± 0.2350.770 ± 0.169
IVA: Day 72.15 ± 1.271.40 ± 0.2881.37 ± 0.309
IVA: Day 142.14 ± 1.201.35 ± 0.2311.20 ± 0.402
M1-IVA: Day 11.91 ± 0.5732.34 ± 0.6021.51 ± 0.349
M1-IVA: Day 73.91 ± 1.803.42 ± 0.5342.65 ± 0.434
M1-IVA: Day 144.11 ± 1.862.97 ± 0.6403.14 ± 1.32
M6-IVA: Day 10.779 ± 0.3431.29 ± 0.7961.24 ± 0.727
M6-IVA: Day 71.52 ± 0.8892.62 ± 1.201.88 ± 1.21
M6-IVA: Day 141.77 ± 0.9412.26 ± 0.7442.55 ± 2.20
SecondaryPart C: Area Under the Concentration Versus Time Curve During a Dosing Interval (AUCtau) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and IVA and Its Metabolites (M1-IVA and M6-IVA)
Time frame:
Day 1, Day 7, and Day 14
Reported as:
Mean · mcg*h/mL
Part C: Area Under the Concentration Versus Time Curve During a Dosing Interval (AUCtau) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and IVA and Its Metabolites (M1-IVA and M6-IVA)
mcg*h/mLPart C: VX-121 (Cohort C1)Part C: VX-121 (Cohort C2)Part C: VX-121 (Cohort C3)
VX-121: Day 13.51 ± 0.8137.96 ± 0.7891.18 ± 0.130
VX-121: Day 721.7 ± 10.635.4 ± 8.276.52 ± 1.20
VX-121: Day 1426.6 ± 14.541.1 ± 8.297.34 ± 1.63
TEZ: Day 156.1 ± 16.650.9 ± 7.1144.6 ± 11.5
TEZ: Day 7133 ± 51.6103 ± 13.988.8 ± 21.0
TEZ: Day 14138 ± 60.8112 ± 10.487.6 ± 28.6
M1-TEZ: Day 120.7 ± 7.0324.9 ± 6.6120.7 ± 4.99
M1-TEZ: Day 7107 ± 24.8130 ± 22.3109 ± 14.1
M1-TEZ: Day 14139 ± 29.7167 ± 24.7142 ± 27.0
M2-TEZ: Day 16.68 ± 2.499.61 ± 5.517.57 ± 3.18
M2-TEZ: Day 7103 ± 41.1130 ± 46.7117 ± 72.6
M2-TEZ: Day 14143 ± 64.1194 ± 82.7200 ± 144
IVA: Day 16.16 ± 1.365.85 ± 1.644.30 ± 0.504
IVA: Day 718.8 ± 12.311.6 ± 3.2611.0 ± 3.73
IVA: Day 1418.4 ± 10.711.2 ± 2.759.02 ± 2.62
M1-IVA: Day 111.5 ± 3.0114.1 ± 1.689.37 ± 1.97
M1-IVA: Day 732.6 ± 17.327.3 ± 4.7922.3 ± 3.70
M1-IVA: Day 1432.2 ± 17.325.3 ± 4.3524.2 ± 12.3
M6-IVA: Day 14.08 ± 1.639.42 ± 4.834.99 ± 2.99
M6-IVA: Day 715.2 ± 9.3426.5 ± 12.719.2 ± 12.8
M6-IVA: Day 1417.6 ± 10.222.6 ± 8.1926.4 ± 24.3
SecondaryPart C: Pre-dose Plasma Concentration (Ctrough) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and IVA and Its Metabolites (M1-IVA and M6-IVA)
Time frame:
Pre-dose at Day 7 and Day 14
Reported as:
Mean · mcg/mL
Part C: Pre-dose Plasma Concentration (Ctrough) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and IVA and Its Metabolites (M1-IVA and M6-IVA)
mcg/mLPart C: VX-121 (Cohort C1)Part C: VX-121 (Cohort C2)Part C: VX-121 (Cohort C3)
VX-121: Day 70.916 ± 0.3691.37 ± 0.3210.258 ± 0.0426
VX-121: Day 141.24 ± 0.6651.72 ± 0.4520.357 ± 0.0966
TEZ: Day 73.95 ± 1.842.57 ± 0.7762.31 ± 0.735
TEZ: Day 144.55 ± 2.503.27 ± 0.6462.27 ± 0.851
M1-TEZ: Day 74.09 ± 1.224.53 ± 0.5123.96 ± 0.685
M1-TEZ: Day 145.45 ± 1.466.40 ± 1.175.03 ± 1.18
M2-TEZ: Day 74.30 ± 1.665.08 ± 2.064.75 ± 2.97
M2-TEZ: Day 146.20 ± 2.605.51 ± 1.728.63 ± 6.24
IVA: Day 71.33 ± 0.8340.768 ± 0.2300.780 ± 0.317
IVA: Day 141.34 ± 0.8890.750 ± 0.2520.601 ± 0.164
M1-IVA: Day 72.46 ± 1.532.00 ± 0.5891.67 ± 0.334
M1-IVA: Day 142.45 ± 1.371.87 ± 0.5091.73 ± 0.977
M6-IVA: Day 71.28 ± 0.7632.09 ± 1.111.67 ± 1.31
M6-IVA: Day 141.60 ± 0.9261.85 ± 0.7382.27 ± 2.26
SecondaryPart D: Maximum Observed Concentration (Cmax) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and IVA and Its Metabolites (M1-IVA and M6-IVA)
Time frame:
Day 1 and Day 15
Reported as:
Mean · mcg/mL
Part D: Maximum Observed Concentration (Cmax) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and IVA and Its Metabolites (M1-IVA and M6-IVA)
mcg/mLPart D: VX-121/TEZ/IVA
VX-121: Day 10.0553 ± 0.0207
VX-121: Day 150.389 ± 0.116
TEZ: Day 15.38 ± 1.39
TEZ: Day 156.80 ± 2.13
M1-TEZ: Day 11.26 ± 0.162
M1-TEZ: Day 155.56 ± 1.19
M2-TEZ: Day 10.243 ± 0.0629
M2-TEZ: Day 153.99 ± 1.41
IVA: Day 10.745 ± 0.279
IVA: Day 151.47 ± 0.472
M1-IVA: Day 11.34 ± 0.478
M1-IVA: Day 152.69 ± 0.829
M6-IVA: Day 10.531 ± 0.229
M6-IVA: Day 151.17 ± 0.589
SecondaryPart D: Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC[0-last]) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and IVA and Its Metabolites (M1-IVA and M6-IVA)
Time frame:
Day 1 and Day 15
Reported as:
Mean · mcg*h/mL
Part D: Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC[0-last]) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and IVA and Its Metabolites (M1-IVA and M6-IVA)
mcg*h/mLPart D: VX-121/TEZ/IVA
VX-121: Day 10.160 ± 0.0766
VX-121: Day 152.50 ± 1.07
TEZ: Day 121.9 ± 5.48
TEZ: Day 1537.4 ± 16.0
M1-TEZ: Day 14.66 ± 1.42
M1-TEZ: Day 1537.8 ± 14.3
M2-TEZ: Day 10.630 ± 0.213
M2-TEZ: Day 1528.6 ± 13.7
IVA: Day 12.74 ± 1.24
IVA: Day 159.27 ± 4.06
M1-IVA: Day 14.51 ± 1.97
M1-IVA: Day 1516.4 ± 6.70
M6-IVA: Day 11.25 ± 0.529
M6-IVA: Day 157.58 ± 4.49
SecondaryPart D: Pre-dose Plasma Concentration (Ctrough) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and IVA and Its Metabolites (M1-IVA and M6-IVA)
Time frame:
Pre-dose at Day 8, Day 15, and Day 29
Reported as:
Mean · mcg/mL
Part D: Pre-dose Plasma Concentration (Ctrough) of VX-121, TEZ and Its Metabolites (M1-TEZ and M2-TEZ) and IVA and Its Metabolites (M1-IVA and M6-IVA)
mcg/mLPart D: VX-121/TEZ/IVA
VX-121: Day 80.258 ± 0.0834
VX-121: Day 150.348 ± 0.109
VX-121: Day 290.323 ± 0.110
TEZ: Day 81.78 ± 0.525
TEZ: Day 152.01 ± 0.543
TEZ: Day 292.02 ± 0.927
M1-TEZ: Day 84.15 ± 0.648
M1-TEZ: Day 154.52 ± 1.06
M1-TEZ: Day 295.11 ± 1.50
M2-TEZ: Day 83.29 ± 1.41
M2-TEZ: Day 153.76 ± 1.29
M2-TEZ: Day 294.57 ± 2.28
IVA: Day 80.873 ± 0.367
IVA: Day 150.998 ± 0.367
IVA: Day 290.916 ± 0.586
M1-IVA: Day 81.38 ± 0.427
M1-IVA: Day 151.76 ± 0.619
M1-IVA: Day 291.62 ± 0.620
M6-IVA: Day 80.823 ± 0.573
M6-IVA: Day 150.819 ± 0.412
M6-IVA: Day 290.990 ± 0.632
SecondaryPart D: Absolute Change in Sweat Chloride (SwCl) Concentrations

Sweat samples were collected using an approved collection device.

Time frame:
From Baseline Through Day 29
Reported as:
Least squares mean · millimole per liter (mmol/L)
Part D: Absolute Change in Sweat Chloride (SwCl) Concentrations
millimole per liter (mmol/L)Part D: PlaceboPart D: VX-121/TEZ/IVA
Part D: Absolute Change in Sweat Chloride (SwCl) Concentrations2.6 (-19.7 to 24.9)-47.7 (-58.2 to -37.2)
SecondaryPart D: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
From Baseline Through Day 29
Reported as:
Least squares mean · percentage points
Part D: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
percentage pointsPart D: PlaceboPart D: VX-121/TEZ/IVA
Part D: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)-2.0 (-12.9 to 8.9)8.3 (2.8 to 13.8)

Adverse events

Collected over From Day 1 Through Safety Follow-up (up to Day 15 for Part A [except Cohorts A3 and A9], up to Day 26 for Cohort A3, up to Day 34 for Cohort A9, up to Day 20 for Part B, up to Day 24 for Part C and up to Week 9 for Part D). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Pooled Placebo (Cohorts A1-5; Except A3)0/8 (0%)0/8 (0%)1/8 (12.5%)
Part A: VX-121 (Cohort A1)0/5 (0%)0/5 (0%)4/5 (80%)
Part A: VX-121 (Cohort A2)0/6 (0%)0/6 (0%)2/6 (33.3%)
Part A: VX-121 (Cohort A3)0/6 (0%)0/6 (0%)4/6 (66.7%)
Part A: VX-121 (Cohort A4)0/6 (0%)0/6 (0%)1/6 (16.7%)
Part A: VX-121 (Cohort A5)0/6 (0%)0/6 (0%)2/6 (33.3%)
Part A: VX-121 (Cohort A9)0/8 (0%)0/8 (0%)7/8 (87.5%)
Part B: Pooled Placebo (Cohorts B1-4)0/9 (0%)0/9 (0%)7/9 (77.8%)
Part B: VX-121 (Cohort B1)0/6 (0%)0/6 (0%)3/6 (50%)
Part B: VX-121 (Cohort B2)0/6 (0%)0/6 (0%)5/6 (83.3%)
Part B: VX-121 (Cohort B3)0/6 (0%)0/6 (0%)4/6 (66.7%)
Part B: VX-121 (Cohort B4)0/6 (0%)0/6 (0%)5/6 (83.3%)
Part C: Pooled Placebo (Cohorts C1-3)0/6 (0%)0/6 (0%)4/6 (66.7%)
Part C: VX-121 (Cohort C1)0/6 (0%)0/6 (0%)3/6 (50%)
Part C: VX-121 (Cohort C2)0/7 (0%)0/7 (0%)6/7 (85.7%)
Part C: VX-121 (Cohort C3)0/6 (0%)0/6 (0%)3/6 (50%)
Part D: Placebo0/3 (0%)1/3 (33.3%)2/3 (66.7%)
Part D: VX-121/TEZ/IVA0/9 (0%)0/9 (0%)7/9 (77.8%)
Most frequent serious events
Most frequent serious events
EventPart A: Pooled Placebo (Cohorts A1-5; Except A3)Part A: VX-121 (Cohort A1)Part A: VX-121 (Cohort A2)Part A: VX-121 (Cohort A3)Part A: VX-121 (Cohort A4)Part A: VX-121 (Cohort A5)Part A: VX-121 (Cohort A9)Part B: Pooled Placebo (Cohorts B1-4)Part B: VX-121 (Cohort B1)Part B: VX-121 (Cohort B2)Part B: VX-121 (Cohort B3)Part B: VX-121 (Cohort B4)Part C: Pooled Placebo (Cohorts C1-3)Part C: VX-121 (Cohort C1)Part C: VX-121 (Cohort C2)Part C: VX-121 (Cohort C3)Part D: PlaceboPart D: VX-121/TEZ/IVA
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations0/80/50/60/60/60/60/80/90/60/60/60/60/60/60/70/61/30/9
Most frequent other events
Showing 10 of 86
Most frequent other events
EventPart A: Pooled Placebo (Cohorts A1-5; Except A3)Part A: VX-121 (Cohort A1)Part A: VX-121 (Cohort A2)Part A: VX-121 (Cohort A3)Part A: VX-121 (Cohort A4)Part A: VX-121 (Cohort A5)Part A: VX-121 (Cohort A9)Part B: Pooled Placebo (Cohorts B1-4)Part B: VX-121 (Cohort B1)Part B: VX-121 (Cohort B2)Part B: VX-121 (Cohort B3)Part B: VX-121 (Cohort B4)Part C: Pooled Placebo (Cohorts C1-3)Part C: VX-121 (Cohort C1)Part C: VX-121 (Cohort C2)Part C: VX-121 (Cohort C3)Part D: PlaceboPart D: VX-121/TEZ/IVA
HeadacheNervous system disorders1/80/52/61/60/60/64/82/92/60/60/61/61/60/64/72/60/31/9
AlopeciaSkin and subcutaneous tissue disorders0/80/50/60/60/60/60/81/90/60/60/63/60/60/60/70/60/30/9
Back painMusculoskeletal and connective tissue disorders0/80/50/60/60/60/60/84/90/60/61/61/61/60/60/70/60/30/9
NasopharyngitisInfections and infestations0/80/50/60/60/60/61/80/90/60/60/60/61/60/63/70/60/30/9
DiarrhoeaGastrointestinal disorders0/80/50/61/60/60/60/80/90/60/60/60/60/60/60/72/60/30/9
FatigueGeneral disorders0/81/50/60/60/60/62/80/90/60/60/60/60/60/61/70/61/31/9
Vessel puncture site bruiseGeneral disorders0/80/50/61/60/60/60/80/90/62/61/60/60/60/60/70/60/30/9
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations0/80/50/60/60/60/60/80/90/60/60/60/60/60/60/70/61/32/9
Arthropod biteInjury, poisoning and procedural complications0/80/50/60/60/60/60/81/90/62/60/60/60/60/61/70/60/30/9
DizzinessNervous system disorders0/80/50/60/60/60/61/80/90/61/60/60/62/62/62/70/60/30/9

Baseline characteristics

Analysis population included all participants who received at least 1 dose of study drug. The participant who participated in Parts A2 and B3 counted only once in Part A: VX-121 (Cohort A2) reporting arm.

Age, Categorical
Age, Categorical(Participants)Part A: Pooled Placebo (Cohorts A1-5; Except A3)Part A: VX-121 (Cohort A1)Part A: VX-121 (Cohort A2)Part A: VX-121 (Cohort A3)Part A: VX-121 (Cohort A4)Part A: VX-121 (Cohort A5)Part A: Cohort A9Part B: Pooled Placebo (Cohorts B1-4)Part B: VX-121 (Cohort B1)Part B: VX-121 (Cohort B2)Part B: VX-121 (Cohort B3)Part B: VX-121 (Cohort B4)Part C: Pooled Placebo (Cohorts C1-3)Part C: VX-121 (Cohort C1)Part C: VX-121 (Cohort C2)Part C: VX-121 (Cohort C3)Part D: PlaceboPart D: VX-121/TEZ/IVATotal
<=18 years0000000000000000000
Between 18 and 65 years856666896656667639114
>=65 years0000000000000000000
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Pooled Placebo (Cohorts A1-5; Except A3)Part A: VX-121 (Cohort A1)Part A: VX-121 (Cohort A2)Part A: VX-121 (Cohort A3)Part A: VX-121 (Cohort A4)Part A: VX-121 (Cohort A5)Part A: Cohort A9Part B: Pooled Placebo (Cohorts B1-4)Part B: VX-121 (Cohort B1)Part B: VX-121 (Cohort B2)Part B: VX-121 (Cohort B3)Part B: VX-121 (Cohort B4)Part C: Pooled Placebo (Cohorts C1-3)Part C: VX-121 (Cohort C1)Part C: VX-121 (Cohort C2)Part C: VX-121 (Cohort C3)Part D: PlaceboPart D: VX-121/TEZ/IVATotal
Female0000110100000010015
Male856655886656666638109
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: Pooled Placebo (Cohorts A1-5; Except A3)Part A: VX-121 (Cohort A1)Part A: VX-121 (Cohort A2)Part A: VX-121 (Cohort A3)Part A: VX-121 (Cohort A4)Part A: VX-121 (Cohort A5)Part A: Cohort A9Part B: Pooled Placebo (Cohorts B1-4)Part B: VX-121 (Cohort B1)Part B: VX-121 (Cohort B2)Part B: VX-121 (Cohort B3)Part B: VX-121 (Cohort B4)Part C: Pooled Placebo (Cohorts C1-3)Part C: VX-121 (Cohort C1)Part C: VX-121 (Cohort C2)Part C: VX-121 (Cohort C3)Part D: PlaceboPart D: VX-121/TEZ/IVATotal
Hispanic or Latino0011011000000100005
Not Hispanic or Latino855565796656657639109
Unknown or Not Reported0000000000000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: Pooled Placebo (Cohorts A1-5; Except A3)Part A: VX-121 (Cohort A1)Part A: VX-121 (Cohort A2)Part A: VX-121 (Cohort A3)Part A: VX-121 (Cohort A4)Part A: VX-121 (Cohort A5)Part A: Cohort A9Part B: Pooled Placebo (Cohorts B1-4)Part B: VX-121 (Cohort B1)Part B: VX-121 (Cohort B2)Part B: VX-121 (Cohort B3)Part B: VX-121 (Cohort B4)Part C: Pooled Placebo (Cohorts C1-3)Part C: VX-121 (Cohort C1)Part C: VX-121 (Cohort C2)Part C: VX-121 (Cohort C3)Part D: PlaceboPart D: VX-121/TEZ/IVATotal
American Indian or Alaska Native0000011000000000002
Asian1000201000010010006
Native Hawaiian or Other Pacific Islander0000000000000000000
Black or African American1002001200001100008
White55644546565545553890
More than one race1000001110001010017
Unknown or Not Reported0000000000000001001
08

Study locations

7 sites
  • Academic Medical Center
    Amsterdam, Netherlands
  • HagaZiekenhuis van den Haag
    Den Haag, Netherlands
  • PRA Health Sciences Onderzoekscentrum UMCG
    Groningen, Netherlands
  • UMC St. Radboud
    Nijmegen, Netherlands
  • Erasmus Medical Center
    Rotterdam, Netherlands
  • Heart of England NHS Foundation Trust, Birmingham Heartlands Hospital
    Birmingham, United Kingdom
  • The Medicines Evaluation Unit
    Manchester, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in May 2019, 13 months.

Results were first posted in Jul 2022, 3 years 2 months after primary completion. A results delay was requested in May 2020.

Of 26 phase 1/2 interventional studies under Cystic Fibrosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2018
First posted
Dec 7, 2018
StartActual
Mar 20, 2018
Primary completionActual
May 3, 2019
CompletionActual
May 3, 2019
Results delay requested
May 1, 2020
Results first posted
Jul 14, 2022
Last update
Jul 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03768089
Responsible party
Sponsor
First posted
Dec 7, 2018
Start date
Mar 20, 2018
Primary completion
May 3, 2019
Completion
May 3, 2019
Results posted
Jul 14, 2022
Last update
Jul 14, 2022

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vanzacaftor · Tezacaftor · Ivacaftor

Start the discussion